Although PCSK9 inhibition therapy may lead to a slight increase in hyperglycemia, this increase is not significant enough to induce new-onset diabetes mellitus (Guo Y. et al., 2021; Carugo et al., 2022). The gene discussed is PCSK9; the disease is diabetes mellitus.